Company Headquarters Annual sales US Population

Cure & Pharma Texas 8.5 ` 33.2 Cr.

Merck & Co., Inc. Kenilworth, NJ 8

Sanofi Pharmaceuticals Bridgewater, NJ 4

New Brunswick,
Johnson & Johnson NJ 3.8
Pfizer New York, NY 1.61
Emergent
Biosolutions Gaithersburg, MD 0.287
AstraZenca
Gilead Sciences Foster City, CA 9

Novavax Inc. Rockville, MD 0.019

Inovio Plymouth
Pharmaceuticals Meeting, PA 0.04
35.256
On a 3 average basis top 10 companies have 90% of the total US Vaccine market
Industry Revenue Phases Year BioNtech Cure & Pharma Sanofi Pharmaceuticals
42.3072 1 2021 0.5 0.5 0.2
2 2021 0.5 0.8 0.4
3 2021 1 1 0.6
4 2022 1.1 1.1 0.8
5 2022 1.1 1.1 0.8
6 2023 1.2 1.2 1
7 2023 1.2 1.2 1

Cure &
Phases Year Pharma Price ($) Revenue

1 2021 0.5 25 12.5

2 2021 0.8 25 20
3 2021 1 27 27
4 2022 1.1 29 31.9
5 2022 1.1 31 34.1
6 2023 1.2 33 39.6
7 2023 1.2 35 42
Total 6.9 207.1

In US market , after a thorough analysis of major trends and cost understanding , we believe t
 AstraZenca Gilead Sciences Other Players (Mainly Johnson&Johnson) Population to be covered
0.5 0.3 0 2
0.8 0.7 0.8 4
0.8 0.8 0.8 5
0.8 0.8 0.4 5
0.8 0.8 0.4 5
1 0.8 0.8 6
1 0.8 0.8 6
33

Gilead S
1
Sanofi Pharmac

derstanding , we believe the initial price for the vaccine would be close to the values we have taken in our analysis. Also since there are a l
 USA
Other Players (Mainly
Johnson&Johnson)
Gilead Sciences
AstraZenca
Sanofi Pharmaceuticals
Cure & Pharma
BioNtech
0 1 2 3 4 5 6 7 8

2021 2021 2021 2022 2022 2023 2023

Chart Title
Gilead Sciences

Sanofi Pharmaceuticals

BioNtech
0 1 2 3 4 5 6 7 8

2021 2021 2021 2022 2022 2023 2023

s. Also since there are a lot of producers available in the US market , so we expect Cure& Pharma to start picking up with the sales eventu
cking up with the sales eventually.
 Rank Company Mar 19 Revenue ( Millions) Brazil Population
Chart Title
1 Bio Manguinhos
7 20.95 Cr
2 Ache 6 996.5
3 EMS Pharma 5
849.1
4 Eurofarma 713.2
4
5 Sanofi 699.2
3
6 Novartis 416.9
2
7 NEO Quimica 390.8
1
4065.7
0 5 1015 20 25
AstraZenca to supply close to 90 million doses,earlier the company had plans to merge with Gilead sciences
Revenue Pricing ($) Demand

Chart Title
1.4
1.2
1
0.8
0.6
0.4
0.2
0
1 2 3 4 5 6 7

Cure & Pharma Serum and Bharat Biotech

AstraZenca Gilead Sciences
Bio Manguinhos All other local Players
 AstraZen Gilead Sciences
Phases Cure & Pharma Serum and Bharat Biotech Bio Manguinhos
ca
1 0.2 0.1 0.5 0.1 0.1
2 0.5 0.3 0.5 0.4 0.1
3 0.8 0.6 0.6 0.4 0.6
4 1 0.8 0.5 0.4 0.3
5 1.2 0.8 0.7 0.6 0.7
6 1.2 0.8 0.7 0.6 0.7
7 0.4 0.2 0.3 0.3 0.8

Phases Demand Pricing ($) Revenue

1 0.2 10 2
2 0.5 11 5.5
3 0.8 12 9.6
4 1 14 14
5 1.2 16 19.2
6 1.2 17 20.4
7 0.4 18 7.2
5.3 77.9
All other local Players Population
0 1
0.2 2
0.6 3
0.3 3
0.7 4
0.7 4
0.8 2
 Cure & Bharat
Rank Company Phases Serum
Pharma Biotech
1 Serum 1 0.4 0.7 0.5
2 Bharat Biotech 2 0.67 1.17 0.83
3 Zydus 3 0.93 1.63 1.17 Chart Titl
4 Wockhardt 4 1.3 2.6 2.3
6
5 Syngene 5 1.565 3.12 2.76
6 1.954 3.9 3.45
6 Sanofi Pharmaceuticals 7 2.53 4.2 4
8 3.22 4.4 4
7 Gilead Sciences 9 3.541 4.86 4.42
Astrazenca 10 3.710 1 5.092 3 4.63 4 5 6
19.75 31.68 28.06
Cure & Pharma Serum
Bharat Biotech AstraZenca
Assumptions Gilead Sciences All local Play

Cure &
Phases Pharma Pricing Revenue
1 0.4 4 1.60
2 0.67 4 2.67
3 0.93 4 3.73
4 1.3 5 6.50
5 1.56 5 7.80
6 1.95 6 11.70
7 2.5 6 15.00
8 3.2 7 22.40
9 3.54 8 28.29
10 3.71 9 33.35
19.75211 133.04
 AstraZen Gilead Sciences
All local Players (Mainly BioNtech) Population (Cr.)
ca
0.5 0.4 0.5 3
0.83 0.67 0.83 5
Chart
1.17 Title 0.93 1.17 7
1.2 1.2 1.4 10
1.44 1.44 1.68 12
1.8 1.8 2.1 15
2.2 2.1 2 17
2.4 2.3 2.7 19
2.65 2.54 2.98 21
3 4 2.78
5 6 2.66
7 8 9 10 3.13 22
16.97 16.05 18.49 131
e & Pharma Serum
rat Biotech AstraZenca
ad Sciences All local Players (Mainly BioNtech)

Chart Title
40
35
30
25
20
15
10
5
0
1 2 3 4 5 6 7 8 9 10

Cure & Pharma Pricing Revenue

Phases Year USA Brazil India Total
1 2021 12.5 2 1.60 ₹ 16.10
2 2021 20 5.5 2.67 ₹ 28.17
3 2021 27 9.6 3.73 ₹ 40.33
4 2022 31.9 14 6.50 ₹ 52.40
5 2022 34.1 19.2 7.80 ₹ 61.10
6 2023 39.6 20.4 11.70 ₹ 71.70
7 2023 42 7.2 15.00 ₹ 64.20
8 2023 22.40 ₹ 22.40
9 2024 28.29 ₹ 28.29
10 2024 33.35 ₹ 33.35
Total 207.1 77.9 133.04 ₹ 418.04

USA